A new agreement with OneTwo Analytics AB will allow Glucotrack to leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its continu ...

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

"In March, our production saw a 17% month-over-month increase in blocks won, even as global hashrate and mining difficulty grew," said Fred Thiel, MARA's chairman and CEO. "Our bitcoin holdings ...

Glucotrack (GCTK) announced an agreement with OneTwo Analytics AB. Through this collaboration, Glucotrack will leverage next-generation ...

Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this ...

Revenue increased 23.9% year over year to $379.8 million in FY 2024 Record quarterly revenue of $113.4 million, up 8.4% year over year in Q4 2024 Gross margin increased from 18.7% to 31.5%, a 12.8 ...

Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption ...

Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with ...

Ouster reported quarterly losses of 48 cents per share which beat the analyst consensus estimate of 59 cents per share. The company reported quarterly sales of $30.092 million which beat the analyst ...

Paul Goode, President & CEO, GlucoTrack, was recently a guest on Benzinga's All-Access. GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose Monitoring ...